Drug resistant tuberculosis poses a significant global public health challenge.In 2018,World Health Organization(WHO)listed bedaquiline as one of Group A drugs for the treatment of multi-drug resistant tuberculosis/rifampicin resistant tuberculosis(MDR/RR-TB).In recent years,there has been a continuous accumulation of substantial evidence from global exploration and application of new treatment regimens involving bedaquiline in combination with different drugs and duration.The efficacy and safety of bedaquiline in special populations such as children/adolescents,pregnant women,and the elderly,as well as in patients with comorbidities of MDR/RR-TB are reviewed in this article,aiming to provide insights for its clinical application.
NETL
NSTL
万方数据
